AZITRA INC (AZTR)
AMEXHealth CareBiotechnologySnapshot 2026-09-09
$0.18+3.55%
Close 2026-09-09 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Control and reduce operating losses: Operating loss not reported.
Azitra aims to advance clinical trials with topline data in 2026. The company raised capital through PIPE financing to support development. Operating losses were about $3.9 million in 2026-Q1, showing ongoing investment. The stock is down 41% from its high, reflecting market stress but potential value.
Azitra is loss-making with operating income worsening from negative $2.2 million in 2025-Q4 to negative $3.9 million in 2026-Q1. The company faces legal and regulatory challenges including delisting notices. No revenue is expected in 2026, and EPS estimates remain negative, signaling weak financial health.
The market prices in a re-rating with implied growth of 31.1% over 3 years despite no current revenue or profitability. Our fair value is $0.08, reflecting high risk and uncertainty. The market expects a turnaround but the company’s losses and regulatory issues weigh heavily.
Breaks if: Failure to secure planned capital raises in 2026
Breaks if: Failure to report topline data for key trials by end of 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on advancing clinical trials and new product development. The current thesis state is cautious due to recent mixed performance and high volatility in management execution.
The market seems to have low expectations for AZTR, as it is currently loss-making and has a premium valuation compared to peers. The low fragility tier suggests that the stock is not overly sensitive to negative news at this time.
Fundamentals may remain weak in the near term, with a high probability of an earnings miss due to erratic performance and ongoing losses. Management's focus on advancing clinical trials and managing cash flow will be critical to watch.
The long-term thesis hinges on the outcomes of clinical trials and the ability to manage cash flow effectively. Additionally, sector performance, particularly from leading companies, could influence AZTR's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating loss worsens beyond -$3.93 million or remains flat over next 4 quarters
Continue disciplined capital allocation to manage operating losses and preserve cash runway amid ongoing R&D and clinical expenses.
Stated as a priority in 3 of last 3 quarters. The company reported net losses of $3.9M in 2026-Q1 and $3.3M in 2026-Q2, with cash declining from $10.1M to $6.7M over the same period. Operating losses persist but cash management reflects ongoing capital discipline amid clinical and R&D spending, consistent with management's stated focus.
“Net loss was $3.3 million for the quarter ended June 30, 2026; cash and cash equivalents of $6.7 million.”
“Net loss was $3.9 million for the quarter ended March 31, 2026; cash and cash equivalents of $10.1 million.”
“Net loss was $2.2 million for the quarter ended December 31, 2025.”
In the next 1 to 3 years, AZTR's performance will depend on clinical advancements and market conditions. Not investment advice.